Role of phospholipase A2 on the variations of the choline signal intensity observed by 1H magnetic resonance spectroscopy in brain diseases 1 1 Published on the World Wide Web on 10 August 2000.

Phospholipase A(2) catalyzes the hydrolysis of membrane glycerophospholipids leading to the production of metabolites observable by both 1H and 31P magnetic resonance spectroscopy. The signal of choline-containing compounds (Cho) observed by 1H magnetic resonance spectroscopy is constituted of metabolites of phosphatidylcholine, especially phosphocholine (PCho) and glycerophosphocholine (GPCho). The phosphomonoester (PME) and phosphodiester (PDE) signals observed by 31P magnetic resonance spectroscopy are, respectively, precursors and catabolites of phospholipids. A large number of brain diseases have been reported to cause variations in the intensity of the Cho, PME and PDE signals. Changes in the activity of phospholipase A(2) have been measured in many brain diseases. In this review, the relationships between the results of 1H and 31P magnetic resonance spectroscopy and the phospholipase A(2) assays are analyzed. In many brain diseases, the variation in the Cho signal intensity can be correlated with a stimulation or inhibition of the phospholipase A(2) activity.

[1]  G. Fein,et al.  Abnormal frontal lobe phosphorous metabolism in bipolar disorder. , 1995, The American journal of psychiatry.

[2]  E. Cabré,et al.  Plasma polyunsaturated fatty acids in liver cirrhosis with or without chronic hepatic encephalopathy: a preliminary study. , 1992, JPEN. Journal of parenteral and enteral nutrition.

[3]  L. Horrocks,et al.  Involvement of phospholipase A2 in neurodegeneration , 1997, Neurochemistry International.

[4]  T. Thorne,et al.  Susceptibility to TNF in the presence of inhibitors of transcription or translation is dependent on the activity of cytosolic phospholipase A2 in human melanoma tumor cells. , 1996, Journal of immunology.

[5]  F. Podo.  Tumour phospholipid metabolism , 1999, NMR in biomedicine.

[6]  D. Dubowitz,et al.  Lack of effect of oral choline supplement on the concentrations of choline metabolites in human brain , 1998, Magnetic Resonance in Medicine.

[7]  I. Simone,et al.  Prognostic value of proton magnetic resonance spectroscopy in ischemic stroke. , 1998, Archives of neurology.

[8]  K. Krishnan,et al.  Proton spectroscopy of human brain: Effects of age and sex , 1994, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[9]  Heinrich Sauer,et al.  31Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics—a study including 50 patients and 36 controls , 1998, Biological Psychiatry.

[10]  Jimmy D Bell,et al.  Cerebral proton and phosphorus-31 magnetic resonance spectroscopy in patients with subclinical hepatic encephalopathy. , 1999, Liver.

[11]  B. Miller,et al.  In Vivo Proton Spectroscopy of Intracranial Infections and Neoplasms , 1994, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[12]  N. Minshew,et al.  31P Nuclear Magnetic Resonance Studies of Phosphoglyceride Metabolism in Developing and Degenerating Brain: Preliminary Observations , 1987, Journal of neuropathology and experimental neurology.

[13]  A. Cuadrado,et al.  Activation of type D phospholipase by serum stimulation and ras-induced transformation in NIH3T3 cells. , 1994, Oncogene.

[14]  L. Chang,et al.  Radiologic-pathologic correlation. Cerebral toxoplasmosis and lymphoma in AIDS. , 1995, AJNR. American journal of neuroradiology.

[15]  G B Matson,et al.  Human brain infarction: proton MR spectroscopy. , 1992, Radiology.

[16]  D J Jenden,et al.  In vivo 1H MRS choline: correlation with in vitro chemistry/histology. , 1996, Life sciences.

[17]  N. Minshew,et al.  Chemical characterization of a prominent phosphomonoester resonance from mammalian brain. 31P and 1H NMR analysis at 4.7 and 14.1 tesla , 1986 .

[18]  A. Köppen,et al.  Choline, a precursor of acetylcholine and phospholipids in the brain. , 1993, Progress in brain research.

[19]  W. Steinbrich,et al.  Combined 1H-MR imaging and localized 31P-spectroscopy of intracranial tumors in 43 patients. , 1988, Journal of computer assisted tomography.

[20]  E. Dennis.  Diversity of group types, regulation, and function of phospholipase A2. , 1994, The Journal of biological chemistry.

[21]  Y. Suh,et al.  Cerebral cortical phospholipase A 2 activity of senescence-accelerated mouse is increased in an age-dependent manner , 1997, Neuroscience Research.

[22]  K. Krishnan,et al.  Brain choline in depression: In vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy , 1994, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[23]  P. Dechent,et al.  Neither short-term nor long-term administration of oral choline alters metabolite concentrations in human brain , 1999, Biological Psychiatry.

[24]  K O Lim,et al.  In vivo spectroscopic quantification of the N‐acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: Effects of normal aging , 1999, Magnetic resonance in medicine.

[25]  J R Griffiths,et al.  Aging of the adult human brain: In vivo quantitation of metabolite content with proton magnetic resonance spectroscopy , 1999, Journal of magnetic resonance imaging : JMRI.

[26]  R. Wurtman,et al.  Choline and cholinergic neurons. , 1983, Science.

[27]  Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. , 1997 .

[28]  J. Shapiro,et al.  Effects of hypernatremia on organic brain osmoles. , 1990, The Journal of clinical investigation.

[29]  Jeffrey C. Erlich,et al.  Phospholipid‐Metabolizing Enzymes in Alzheimer's Disease: Increased Lysophospholipid Acyltransferase Activity and Decreased Phospholipase A2 Activity , 1998, Journal of neurochemistry.

[30]  G. Atsumi,et al.  Characterization of heparin low-affinity phospholipase A1 present in brain and testicular tissue. , 1999, Journal of biochemistry.

[31]  G J Barker,et al.  Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia , 1995, Psychological Medicine.

[32]  D M Doddrell,et al.  A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. , 1999, Magnetic resonance imaging.

[33]  Toshiro Fujimoto,et al.  Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report , 1995, Psychiatry Research: Neuroimaging.

[34]  C. Manelfe,et al.  Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. , 1999, Investigative radiology.

[35]  M. Weiner,et al.  Proton MR spectroscopic imaging of the striatum in Parkinson's disease. , 1997, Magnetic resonance imaging.

[36]  B. Ross,et al.  Clinical Applications of Magnetic Resonance Spectroscopy , 1997, Epilepsia.

[37]  W. Thompson,et al.  The triphosphoinositide phosphodiesterase of brain tissue. , 1964, The Biochemical journal.

[38]  Stefan Riehemann,et al.  31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients , 1998, European Archives of Psychiatry and Clinical Neuroscience.

[39]  T. Inubushi,et al.  Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. , 1992, Journal of affective disorders.

[40]  A. J. Kumar,et al.  Proton NMR spectroscopy of Canavan's disease. , 1992, Neuropediatrics.

[41]  N. Kato,et al.  Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders , 1998, European Archives of Psychiatry and Clinical Neuroscience.

[42]  J. Browning,et al.  Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. , 1993, Journal of lipid mediators.

[43]  A. Thompson,et al.  Biochemical changes within a multiple sclerosis plaque in vivo. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[44]  D. Selkoe,et al.  Cytosolic Phospholipase A2(cPLA2) Immunoreactivity Is Elevated in Alzheimer's Disease Brain , 1996, Neurobiology of Disease.

[45]  S. Khushu,et al.  FRONTAL LOBE PROTON MAGNETIC-RESONANCE SPECTROSCOPY IN GRAVES’ DISEASE: A PILOT STUDY , 1998, Psychoneuroendocrinology.

[46]  H. Degani,et al.  Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. , 1996, Anticancer research.

[47]  B D Ross,et al.  Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases , 1998, Neurology.

[48]  S. Bluml,et al.  Proton‐Decoupled 31P Magnetic Resonance Spectroscopy Reveals Osmotic and Metabolic Disturbances in Human Hepatic Encephalopathy , 1998, Journal of neurochemistry.

[49]  Brian D. Ross,et al.  Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases , 1999 .

[50]  P M Matthews,et al.  Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis , 1991, Neurology.

[51]  R. Gross,et al.  Identification of neutral active phospholipase C which hydrolyzes choline glycerophospholipids and plasmalogen selective phospholipase A2 in canine myocardium. , 1985, The Journal of biological chemistry.

[52]  D. Stephenson,et al.  Reactive glia express cytosolic phospholipase A2 after transient global forebrain ischemia in the rat. , 1996, Stroke.

[53]  N Schuff,et al.  Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia. , 2000, The American journal of psychiatry.

[54]  John P. Stack,et al.  1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: Clinical, neurodevelopmental, and cognitive correlates , 1994, Biological Psychiatry.

[55]  A. Stoll,et al.  Decreased brain choline uptake in older adults. An in vivo proton magnetic resonance spectroscopy study. , 1995, JAMA.

[56]  M. Keshavan,et al.  Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. , 1991, Archives of general psychiatry.

[57]  G. Rordorf,et al.  Characterization of phospholipase A2 (PLA2) activity in gerbil brain: enhanced activities of cytosolic, mitochondrial, and microsomal forms after ischemia and reperfusion , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[58]  J. Kanfer,et al.  Phosphatidylethanol Formation via Transphosphatidylation by Rat Brain Synaptosomal Phospholipase D , 1987, Journal of neurochemistry.

[59]  N. Craddock,et al.  Association study of bipolar disorder at the phospholipase A2 gene (PLA2A) in the Darier's disease (DAR) region of chromosome 12q23‐q24.1 , 1996, Psychiatric genetics.

[60]  P. Livrea,et al.  Localised 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV , 1998, Journal of neurology, neurosurgery, and psychiatry.

[61]  T. Holler,et al.  Release of choline from rat brain under hypoxia: contribution from phospholipase A2 but not from phospholipase D , 1993, Brain Research.

[62]  A. Lacroix,et al.  Brain metabolic alterations in Cushing's syndrome as monitored by proton magnetic resonance spectroscopy , 1999, NMR in biomedicine.

[63]  B. Miller.  A review of chemical issues in 1H NMR spectroscopy: N‐acetyl‐l‐aspartate, creatine and choline , 1991, NMR in biomedicine.

[64]  F. Thomson,et al.  Purification of a phosphatidic-acid-hydrolysing phospholipase A2 from rat brain. , 1995, The Biochemical journal.

[65]  Jimmy D Bell,et al.  Cerebral Phosphorus‐31 magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy , 1994, Hepatology.

[66]  K. P. Strickland,et al.  The purification and characterization of a phospholipase A2 activity from the 106,000 X g pellet (microsomal fraction) of bovine brain acting on phosphatidylinositol. , 1982, Canadian journal of biochemistry.

[67]  A. Stoll,et al.  Choline ingestion increases the resonance of choline-containing compounds in human brain: An in vivo proton magnetic resonance study , 1995, Biological Psychiatry.

[68]  O. Kassim,et al.  Macrophage responses to Toxoplasma antigens in vitro: a possible role in inflammatory lesions in toxoplasmosis. , 1999, The American journal of tropical medicine and hygiene.

[69]  G J Barker,et al.  The proton NMR spectrum in acute EAE: The significance of the change in the Cho:Cr ratio , 1993, Magnetic resonance in medicine.

[70]  J. Moscat,et al.  Activation of phosphatidylcholine-specific phospholipase C in cell growth and oncogene transformation. , 1989, Biochemical Society transactions.

[71]  E. Dennis,et al.  The growing phospholipase A2 superfamily of signal transduction enzymes. , 1997, Trends in biochemical sciences.

[72]  B. McEwen,et al.  Glucocorticoids inhibit soluble phospholipase C activity and cytosolic guanine nucleotide regulatory protein-alpha i immunoreactivity in spleen. , 1993, Endocrinology.

[73]  D J Jenden,et al.  In vivo proton magnetic resonance spectroscopy of the normal aging human brain. , 1996, Life sciences.

[74]  B D Ross,et al.  Localized 1H NMR spectroscopy in patients with chronic hepatic encephalopathy. Analysis of changes in cerebral glutamine, choline and inositols , 1991, NMR in biomedicine.

[75]  F. Buonanno,et al.  In Vitro31P NMR Spectroscopy Detects Altered Phospholipid Metabolism in Alzheimer's Disease , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[76]  R. Lenkinski,et al.  1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. , 1994, Academic radiology.

[77]  Tetsuya Takano,et al.  Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia , 1994, Biological Psychiatry.

[78]  R. Kauppinen,et al.  Decrease in brain choline‐containing compounds following a short period of global ischemia in gerbils as detected by 1H NMR spectroscopy in vivo , 1994, NMR in biomedicine.

[79]  M. Weiner,et al.  Decreased phosphorus metabolite concentrations and alkalosis in chronic cerebral infarction. , 1992, Radiology.

[80]  B D Ross,et al.  Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. , 1992, Radiology.

[81]  L. Chang,et al.  Brain lesions in patients with AIDS: H-1 MR spectroscopy. , 1995, Radiology.

[82]  S. Bluml,et al.  Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy? , 1996, Digestive diseases.

[83]  W. Heindel,et al.  Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease , 1996, Journal of magnetic resonance imaging : JMRI.

[84]  T. Nakada,et al.  31P and 3‐fluoro‐3‐deoxy‐D‐glucose 19F In vivo NMR spectroscopy of aged rat brain , 1991, NMR in biomedicine.

[85]  B. Tunggal,et al.  In vivo 13c nuclear magnetic resonance investigations of choline metabolism in rabbit brain , 1990, Magnetic resonance in medicine.

[86]  A. Lacroix,et al.  Recovery of the brain choline level in treated Cushing’s patients as monitored by proton magnetic resonance spectroscopy , 2000, Brain Research.

[87]  L. Horrocks,et al.  Identification and Purification of Calcium‐Independent Phospholipase A2 from Bovine Brain Cytosol , 1992, Journal of neurochemistry.

[88]  E. Adalsteinsson,et al.  Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder , 1998, Biological Psychiatry.

[89]  Detection of neutral active phosphatidylcholine-specific phospholipase C in Friend leukemia cells before and after erythroid differentiation. , 1993, Anticancer research.

[90]  T. Ernst,et al.  Abnormal cerebral metabolite concentrations in patients with probable alzheimer disease , 1994, Magnetic resonance in medicine.

[91]  S. Kish,et al.  Characterization of a Novel Phospholipase A2 Activity in Human Brain , 1995, Journal of neurochemistry.

[92]  G. Yadid,et al.  Brain Phospholipase A2 Is Activated After Experimental Closed Head Injury in the Rat , 1989, Journal of neurochemistry.

[93]  R. Roman,et al.  Transduction of physical force by the vascular wall Role of phospholipase C and cytochrome P450 metabolites of arachidonic acid. , 1995, Trends in cardiovascular medicine.

[94]  Ponnada A. Narayana,et al.  Proton magnetic resonance spectroscopy in multiple sclerosis , 1990, Neurology.

[95]  J. Rotrosen,et al.  Elevated PLA2 activity in schizophrenics and other psychiatric patients , 1993, Biological Psychiatry.

[96]  B. Rosen,et al.  Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.

[97]  L. Horrocks,et al.  Plasmalogens, phospholipases A2 and signal transduction , 1995, Brain Research Reviews.

[98]  E Moore,et al.  Serial precision of metabolite peak area ratios and water referenced metabolite peak areas in proton MR spectroscopy of the human brain. , 1998, Magnetic resonance imaging.

[99]  G Tedeschi,et al.  Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. , 1996, The American journal of psychiatry.